<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779220</url>
  </required_header>
  <id_info>
    <org_study_id>JA21963</org_study_id>
    <nct_id>NCT00779220</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group, Study to Evaluate the Efficacy, Safety and PK/PD of Ocrelizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety and PK/PD of ocrelizumab at each dose in
      combination with methotrexate（MTX）in patients with active rheumatoid arthritis (RA). The data
      from this study will also be compared with those from a clinical study of ocrelizumab in
      patients with active RA that was conducted in the U.S.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the efficacy, safety and PK/PD of ocrelizumab at each dose in
      combination with MTX in patients with active RA. The data from this study will also be
      compared with those from a clinical study of ocrelizumab in patients with active RA that was
      conducted in the U.S.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with ACR20 response.</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ACR20, 50, and 70 response, and the components of this outcome.</measure>
    <time_frame>very 4 Weeks, from Week 4 to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EULAR response rate.</measure>
    <time_frame>Every 4 Weeks, from Week 4 to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS 28, HAQ-DI score.</measure>
    <time_frame>Every 4 Weeks, from Week 4 to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACIT Fatigue Scale score</measure>
    <time_frame>Weeks 4,12,and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weeks 4,12,and 24</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of human anti-human(ocrelizumab) antibodies (HAHA)</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and Pharmacodynamics of ocrelizumab.</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ocrelizumabu 50mg</intervention_name>
    <description>Intravenous repeating dose (50mg)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ocrelizumabu 200mg</intervention_name>
    <description>Intravenous repeating dose (200mg)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ocrelizumab 500mg</intervention_name>
    <description>Intravenous repeating dose (500mg)</description>
    <arm_group_label>4:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA for ≧6 months according to the revised 1987 ACR criteria for the
             classification of RA.

          -  Adult patients, ≧20 years of age.

          -  Receiving methotrexate at a dose of 6 to 8mg/week（oral）for ≧12 weeks, with a stable
             dose for the last 4 weeks before treatment.

          -  Positive serum RF.

        Exclusion Criteria:

          -  Rheumatic autoimmune disease other than RA, or Significant systemic involvement
             secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or
             Felty's syndrome).Patients with secondary Sjögren's syndrome or secondary limited
             cutaneous vasculitis with RA are eligible.

          -  Functional Class Ⅳ as defined by the ACR Classification of Functional Status in RA.

          -  History of or current inflammatory joint disease other than RA (e.g., gout, reactive
             arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or
             other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory
             bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or
             other overlap syndrome).

          -  Any surgical procedure (except for minor surgeries requiring local or no anaesthesia
             and without any complications or sequelae) within 12 weeks prior to or planned within
             24 weeks after baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naritoshi Mochidome</last_name>
    <role>Study Chair</role>
    <affiliation>Chugai Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chubu region</name>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chugoku region</name>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido Region</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto Region</name>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki Region</name>
      <address>
        <city>Kinki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyusyu region</name>
      <address>
        <city>Kyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sikoku region</name>
      <address>
        <city>Sikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

